Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML

(2011) G. V. Helgason et al.   BLOOD

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

(2011) W. Warsch et al.   BLOOD

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Advances in the treatment of chronic myeloid leukemia

(2011) Anna M Eiring et al.   BMC Medicine

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

(2011) Wayne W. Chan et al.   CANCER CELL

Antigens in chronic myeloid leukemia: implications for vaccine development

(2011) Michal Šmahel   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

(2011) Florian Grebien et al.   CELL

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks: Figure 1.

(2011) Francesca Pellicano et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

(2011) Seiichi Okabe et al.   Journal of Hematology & Oncology

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

(2011) E K Allan et al.   LEUKEMIA

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

(2011) Carine Tang et al.   LEUKEMIA & LYMPHOMA

Generation of iPSCs from cultured human malignant cells

(2010) J. E. Carette et al.   BLOOD

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(2010) Bin Zhang et al.   CANCER CELL

The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge

(2010) Franck E. Nicolini et al.   Clinical Lymphoma Myeloma & Leukemia

CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity

(2010) Henrik Gréen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

(2010) Kevin R. Kelly et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

(2010) Guoqing Wei et al.   Journal of Hematology & Oncology

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene

(2010) C Nishioka et al.   LEUKEMIA

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

(2010) D M Ross et al.   LEUKEMIA

BCR-ABL peptide vaccination in healthy subjects: Immunological responses are equivalent to those in chronic myeloid leukaemia patients

(2010) José M. Rojas et al.   LEUKEMIA RESEARCH

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

(2010) Jianming Zhang et al.   NATURE

TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

(2010) Kazuhito Naka et al.   NATURE

Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination

(2010) Monica Bocchia et al.   Nature Reviews Clinical Oncology

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

(2010) Nathalie Carayol et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Response definitions and European Leukemianet Management recommendations

(2009) Michele Baccarani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

(2009) Y. Shiotsu et al.   BLOOD

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

(2009) L. Noens et al.   BLOOD

Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease

(2009) Nitin Jain et al.   CANCER

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

(2009) Yesid Alvarado et al.   CANCER

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib

(2009) Sophia Hatziieremia et al.   EXPERIMENTAL HEMATOLOGY

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

(2009) Cristian Bellodi et al.   JOURNAL OF CLINICAL INVESTIGATION

HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia

(2009) Mukta Arora et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

(2009) Jane F. Apperley et al.   JOURNAL OF CLINICAL ONCOLOGY

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia

(2009) Hugues de Lavallade et al.   LEUKEMIA RESEARCH

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

(2009) Chen Zhao et al.   NATURE

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

(2009) Yaoyu Chen et al.   NATURE GENETICS

Glycogen synthase kinase 3  missplicing contributes to leukemia stem cell generation

(2009) A. E. Abrahamsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

(2009) D. Bixby et al.   Hematology-American Society of Hematology Education Program

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

(2008) E. Jabbour et al.   BLOOD

BCR/ABL Inhibits Mismatch Repair to Protect from Apoptosis and Induce Point Mutations

(2008) T. Stoklosa et al.   CANCER RESEARCH

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

(2008) Michael G. Kharas et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

(2008) J Cortes et al.   LEUKEMIA

PML targeting eradicates quiescent leukaemia-initiating cells

(2008) Keisuke Ito et al.   NATURE